Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Inspire Veterinary Partners (IVPR) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Inspire Veterinary Partners (IVPR) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Inspire Veterinary Partners' Cash from Financing Activities fell 7846.83% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 4509.09%. This contributed to the annual value of $10.6 million for FY2024, which is 8824.11% up from last year.
  • As of Q3 2025, Inspire Veterinary Partners' Cash from Financing Activities stood at $1.5 million, which was down 7846.83% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Inspire Veterinary Partners' Cash from Financing Activities registered a high of $7.0 million during Q3 2024, and its lowest value of -$187445.0 during Q2 2024.
  • Its 4-year average for Cash from Financing Activities is $2.3 million, with a median of $1.4 million in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 13252.2% in 2024, then surged by 79154.79% in 2025.
  • Inspire Veterinary Partners' Cash from Financing Activities (Quarter) stood at $6.3 million in 2022, then tumbled by 89.14% to $682789.0 in 2023, then fell by 19.18% to $551846.0 in 2024, then skyrocketed by 173.44% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.3 million for Q2 2025, and $2.5 million during Q1 2025.